Premium
Which is the best foot to put forward in recurrent ovarian cancer?
Author(s) -
Rose Peter G.
Publication year - 2011
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.26615
Subject(s) - carboplatin , medicine , docetaxel , ovarian cancer , oncology , chemotherapy , combination chemotherapy , surgery , cancer , cisplatin
This investigation of sequential versus combination chemotherapy for platinum‐sensitive, recurrent ovarian cancer uses a study design that involves giving sequential docetaxel followed by carboplatin. On the basis of the improved progression‐free rate with the combination, use of a nonplatinum agent as the first of the sequential therapies in a platinum‐sensitive patient may not be putting the best foot forward.